Summary
Percutaneous coronary intervention is the primary treatment for patients with acute coronary syndrome. Selective use of manual thrombectomy may be an effective option. P2Y12 inhibitors are a treatment of choice in patients with STEMI. Bivalirudin reduces adverse cardiac events and is associated with reduced bleeding. When percutaneous coronary intervention is delayed in patients with STEMI, fibrinolytic therapy should be administered.
- acute coronary syndrome
- bivalirudin
- fibrinolytic therapy
- glycoprotein IIb/IIIa
- Impella
- intraaortic balloon pump
- P2Y12 inhibitors
- NSTEMI
- percutaneous coronary intervention
- pharmacoinvasive
- STEMI
- thrombin inhibitor
- pharmacology
- cardiology & cardiovascular medicine guidelines
- interventional techniques & devices
- © 2015 SAGE Publications
Tools
Table of contents
Cited By...
- No citing articles found.